The immune system simply cannot see them to attack them.
In the long struggle to make the immune system a reliable ally against cancer, certain tumors have remained stubbornly invisible to its gaze. At the University of Miami's Sylvester Comprehensive Cancer Center, researchers are testing whether a carefully chosen virus might serve as a lantern — illuminating high-grade neuroendocrine tumors so that immunotherapy can finally do its work. The trial is early, but it is built on a coherent logic: understand precisely why a treatment fails, then engineer a way around that failure.
- High-grade neuroendocrine tumors are rare but lethal, and patients have little to reach for beyond chemotherapy as immunotherapy consistently fails them.
- The core problem is invisibility — these tumors evade immune detection so completely that checkpoint inhibitors, which have transformed cancer care elsewhere, find nothing to target.
- Researchers are deploying SVV-001, an oncolytic virus that replicates inside tumor cells and strips away the molecular camouflage, exposing cancer-specific markers the immune system can finally recognize.
- The virus zeroes in on TEM8, a biomarker linked to the most aggressive cancer behavior, sparing healthy tissue while flagging the most dangerous cells for immune attack.
- The first phase of the trial — three dose levels, single injections — has passed without severe side effects, and the study is now expanding toward multiple doses and genetic tracking of patient response.
- If the approach holds, it could redefine treatment for a category of cancers that research has long underserved, offering a replicable model for breaking immunotherapy resistance.
At the University of Miami's Sylvester Comprehensive Cancer Center, a clinical trial is testing whether a virus can do what medicine has so far failed to accomplish: make aggressive neuroendocrine tumors visible to the immune system.
High-grade neuroendocrine tumors are rare, fast-moving, and resistant to the immunotherapy drugs that have reshaped cancer treatment over the past decade. Checkpoint inhibitors — drugs that release the brakes on immune cells — have little effect because these tumors evade immune recognition entirely. Chemotherapy remains the default, and progress has been slow. The disease is uncommon enough to attract limited research investment, but not uncommon enough to ignore.
The Sylvester team's answer is SVV-001, a Seneca Valley virus engineered to replicate inside tumor cells and destroy them. As it does, it disrupts the tumor's structure and exposes cancer-specific molecules the immune system can recognize. Once that veil is lifted, checkpoint inhibitors — nivolumab and ipilimumab — are administered, and immune cells can finally identify and attack their target. The virus homes in on a biomarker called TEM8, which marks the most aggressive cancer cells while leaving healthy tissue untouched. A study published in early 2026 confirmed that TEM8 presence correlates with worse outcomes and greater metastatic spread.
The trial launched in 2025 and has completed its first three dose levels, each involving a single viral injection followed by immunotherapy. No severe treatment-related side effects have emerged. The next phase will escalate to up to six doses before immunotherapy begins, with genetic sequencing used to track how TEM8 expression shapes individual patient responses.
For patients with high-grade neuroendocrine tumors, the trial offers something that has been genuinely scarce — not a promise, but a direction grounded in a clear-eyed understanding of why current treatments fail and a testable idea about how to move past them.
At the University of Miami's Sylvester Comprehensive Cancer Center, researchers are testing a deceptively simple idea: what if you could use a virus to help the immune system see cancer it has been missing?
High-grade neuroendocrine tumors are rare and vicious. They grow quickly, spread aggressively, and resist the immunotherapy drugs that have transformed treatment for many other cancers. For patients diagnosed with these tumors, the options narrow fast. Chemotherapy remains the default. Progress has been slow because the disease itself is uncommon—not uncommon enough to ignore, but uncommon enough that it has attracted limited research investment and fewer breakthrough treatments.
The problem, as Dr. Chinmay Jani explains it, is that these tumors are expert at hiding. Checkpoint inhibitors—immunotherapy drugs that work by releasing the brakes on immune cells—have revolutionized cancer care in many settings. But they fail against high-grade neuroendocrine cancers because the tumors evade immune recognition entirely. The immune system simply cannot see them to attack them. "Immunotherapy has revolutionized cancer treatment," Jani said. "But it still has a lot of issues, including resistance, and many patients are non-responders. This trial is about improving immunotherapy."
The Sylvester team's approach is to deploy a biological tool called Seneca Valley virus, or SVV-001. This is an oncolytic virus—a virus engineered to grow inside tumors and destroy them. But its real power in this trial lies in what happens when it does. As SVV-001 replicates within cancer cells, it disrupts the tumor's structure and exposes cancer-specific molecules that the immune system can recognize. The virus essentially lifts the veil. Then, when checkpoint inhibitors are administered—specifically nivolumab and ipilimumab—the immune cells can finally see their target and attack.
The virus targets a specific biomarker called TEM8, which appears on aggressive cancer cells but not on healthy tissue in the lungs, ovaries, pancreas, stomach, uterus, breast, or colon. In a study published in March 2026, Jani's team identified TEM8 as a marker of poor outcomes—its presence correlates with increased tumor aggressiveness and metastasis. By targeting TEM8, SVV-001 can strike at the most dangerous cancer cells with precision.
The trial began in 2025 and has now completed its first three dose levels. In this initial phase, patients received a single injection of SVV-001 followed by immunotherapy. The results so far have been clean: no severe treatment-related side effects at any dose level tested. The next phase will push further, giving patients up to six doses of the virus before immunotherapy. Researchers will use genetic sequencing to track how TEM8 expression influences outcomes, building a map of which patients benefit most.
Dr. Gilberto Lopes, chief of medical oncology at Sylvester, frames the work as part of a broader institutional commitment to diseases that have been left behind. "Many tumors evade immune detection," he said. "This study evaluates whether SVV-001 can expose cancer cells and enhance the effectiveness of checkpoint inhibitors." The team is actively enrolling patients as the trial advances, moving toward the optimal dose level that will define the next stage of testing.
This is early-stage science, and caution is warranted. But for patients with high-grade neuroendocrine tumors, the trial represents something that has been scarce: a new direction, grounded in a clear understanding of why current treatments fail, and a testable hypothesis about how to fix it.
Notable Quotes
Immunotherapy has revolutionized cancer treatment. But it still has a lot of issues, including resistance, and many patients are non-responders. This trial is about improving immunotherapy.— Dr. Chinmay Jani, Sylvester chief fellow in hematology and oncology
Many tumors evade immune detection; this study evaluates whether SVV-001 can expose cancer cells and enhance the effectiveness of checkpoint inhibitors.— Dr. Gilberto Lopes, chief of medical oncology at Sylvester
The Hearth Conversation Another angle on the story
Why does this virus approach work when standard immunotherapy alone doesn't?
The tumor is essentially invisible to the immune system. The virus goes in and tears the tumor apart, exposing the cancer's identity. Once the immune system can see what it's fighting, the checkpoint inhibitors can do their job.
And the virus doesn't harm healthy cells?
That's the precision part. SVV-001 targets TEM8, a marker that appears on aggressive cancer cells but nowhere in normal tissue. It's like a lock that only fits on the tumor.
What happens in the next phase of the trial?
Patients will receive multiple doses of the virus instead of just one, then immunotherapy. The researchers want to find the sweet spot—enough virus to expose the cancer, but not so much that side effects become a problem.
How many patients are we talking about?
The trial is still enrolling. Right now they've completed the first three dose levels, but the real expansion happens once they identify the optimal dose.
What's the timeline for knowing if this actually works?
That depends on how the next phases go. Phase I is about safety, which they're establishing now. But efficacy—whether patients actually survive longer or see their tumors shrink—that takes longer to measure.
Why hasn't this been tried before?
High-grade neuroendocrine tumors are rare. They haven't attracted the research funding or attention that more common cancers have. This trial exists because Sylvester decided to focus on exactly those forgotten diseases.